Inside the Study for a Remedy to Fight Congo’s Deadliest Ebola Outbreak – WTOP News
The study is testing obeldesivir as post-exposure protection for people exposed to Ebola, with nearly 1,000 adults and children targeted for enrollment.
- More than 250 people have enrolled in an EBO-PEP clinical trial in Ituri Province, Democratic Republic of Congo, testing Gilead's experimental antiviral pill, obeldesivir, to prevent Ebola infection after suspected contact.
- Health authorities are battling the country's deadliest Ebola outbreak, which has caused at least 8,300 confirmed cases and 4,000 deaths since May, driven by the rare Bundibugyo virus strain.
- The EBO-PEP study aims to recruit nearly 1,000 people exposed within five days, providing post-exposure prophylaxis and daily in-person monitoring for 21 days with a final check at 42 days.
- Investigating physician Jacques Zawadi of ALIMA noted most participants are satisfied, yet the study faces disruptions when emotionally affected participants learn of family deaths. "This is the biggest challenge we face," Zawadi said.
- Authorities are also studying whether the Ervebo vaccine offers protection against Bundibugyo, while obeldesivir could provide a faster alternative to break the infection chain compared to vaccines requiring days to take effect.
14 Articles
14 Articles
In the Democratic Republic of the Congo, more than 250 people are participating in the Oeldesivir test, a drug that can prevent Ebola from developing after contact with the virus.
Congo tests drug that can prevent Ebola infection <p>More than 250 people in Congo are testing obeldesivir after contact with the Ebola virus. Research plans to expand to nearly 1,000 participants.</p>
Remedy tested to fight Congo's deadliest Ebola outbreak
RWAMPARA, Congo — More than 250 participants have been enrolled in a trial for a drug that could stop them from contracting Ebola in Congo, in what experts have described as a critical step to try to fight the deadliest outbreak of the disease in the Central African country.
Inside the study for a remedy to fight Congo’s deadliest Ebola outbreak – WTOP News
RWAMPARA, Congo (AP) — More than 250 participants have been enrolled in a trial for a drug that could stop them from contracting Ebola in Congo, in what experts have described as a critical step to try to fight the deadliest outbreak of the disease in the Central African country. The drug is targeted at Bundibugyo virus, which is responsible for the fast-moving outbreak and is without an approved vaccine or treatment. The trial began in July and…
Coverage Details
Bias Distribution
- 43% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
